All Q1 FY26 results →

PM

Poly Medicure

Q1 FY26

Poly Medicure Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,594

Market cap₹16.2K Cr

P/E50.5

Updated16 Oct 2026

Read4 min read

The short version

Citieffe delivered revenue of approximately €17.3 million in 2024 with 15% YoY growth; EBITDA grew 14% to €3.1 million. Citieffe delivered a 15% revenue growth and 14% EBITDA growth in 2024, signaling strong performance.

From Poly Medicure's Q1 FY26 earnings-call transcript · updated 16 Oct 2026.

Revenue & Sales Performance

Citieffe delivered revenue of approximately €17.3 million in 2024 with 15% YoY growth; EBITDA grew 14% to €3.1 million.
Management expects to double revenue over the next 5 years without significant capex, leveraging existing 60% capacity with potential third shift.
Introduction of plates to complement existing nails and screws product portfolio aims to capture more tenders and increase sales.
Expansion into Indian market and other geographies where Citieffe has limited presence is being evaluated to grow volumes.
Planned R&D to add 3-5 new or enhanced products annually, strengthening product offerings.

2 more points from Poly Medicure's call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

Citieffe delivered a 15% revenue growth and 14% EBITDA growth in 2024, signaling strong performance.
Management expects to introduce 3-5 new products annually, enhancing growth prospects.
Expansion plans include adding plates to the portfolio, which currently limits participation in some tenders.
Synergies anticipated from leveraging Polymed's global distribution network and R&D capabilities.
Margin expansion expected due to operating leverage as revenue grows from existing capacity without significant capex.
The company aims to double revenue in the next 5 years with only modest capex (~€1.5-2 million annually).

2 more points from Poly Medicure's call on margins

Pro opens every point from 15K+ earnings calls

See what Poly Medicure said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Current annual capex for Citieffe is between €1.5 million to €2 million, covering regular maintenance and instrumentation needs for trauma surgeries.
The existing manufacturing facility in Bologna, Italy is at 60% capacity utilization with potential to add a third shift, providing significant headroom for near-term growth without major capex.
No immediate plans to move manufacturing from Italy to India; current facility is doing a very good job.
Future capex required to expand production capacity is expected to be minimal in the near term.

2 more points from Poly Medicure's call on capex

Pro opens every point from 15K+ earnings calls

Fundraising & Capital Structure

No specific mention of any current or immediate future fundraising through debt or equity was made in the discussion on the call.
The company referred to past investments and capital infusion by previous owners but did not discuss new fundraising plans.
Polymed highlighted that regular capex needs for the acquired company (Citieffe) are around EUR 1.5 to 2 million a year, manageable within current operations.

2 more points from Poly Medicure's call on fundraising

Pro opens every point from 15K+ earnings calls

See what Poly Medicure said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders for Poly Medicure Limited or its acquisitions, including Citieffe Group. However, some relevant insights related to business growth and market opportunities can be summarized: - Citieffe had revenue of approximately $17.3 million in 2024 with 15% year-on-year growth. - Citieffe operates at about 60% capacity utilization with room to expand production without significant capex. - The orthopedic trauma and extremities market is large ($12 billion) and growing fast (6-7%).

2 more points from Poly Medicure's call on order book

Pro opens every point from 15K+ earnings calls

Poly Medicure — Quarterly revenue & net profit

Revenue Net profit

Dec 2024Q3 FY25

Mar 2025Q4 FY25

Jun 2025Q1 FY26

Sep 2025Q2 FY26

Dec 2025Q3 FY26

Mar 2026Q4 FY26

Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹535 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Poly Medicure Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

OSEL Devices (Q1 FY26)
FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. Key concall takeaways from OSEL Devices Ltd's Q1 FY26 earnings call…
QMS Medical Allied Services Ltd (Q1 FY26)
25 crores in FY'26. Key concall takeaways from QMS Medical Allied Services Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Laxmi Dental Ltd (Q1 FY26)
68 crores over two years planned to support expansion. Key concall takeaways from Laxmi Dental Ltd's Q1 FY26 earnings call — and how it ranks against sector…

Compare:vs Molbio Diagnosti vs Laxmi Dental Ltd vs Hemant Surgical Industries Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Poly Medicure and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Poly Medicure Q1 FY26 results?

Citieffe delivered revenue of approximately €17.3 million in 2024 with 15% YoY growth; EBITDA grew 14% to €3.1 million. Citieffe delivered a 15% revenue growth and 14% EBITDA growth in 2024, signaling strong performance.

What is Poly Medicure share price analysis?

Poly Medicure currently shows a neutral. The stock trades at a P/E of 50.5 with a market cap of ₹16,155 Cr. Investors should review the full earnings analysis for detailed insights.

Is Poly Medicure planning capital expenditure?

Current annual capex for Citieffe is between €1.5 million to €2 million, covering regular maintenance and instrumentation needs for trauma surgeries.

Keep Poly Medicure on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.